27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Through deinstitutionalization, more adults with mental retardation are living in the community under the care of family physicians. 3 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Through systematic instruction and retraining visual and sustained attention, the patient was able to engage meaningfully with a high-tech device to increase functional personal choice when supported by a partner. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Precision nutrition is a tailored dietary approach that considers an individual’s genetic and metabolic profile, lifestyle factors, and specific nutritional needs to improve health and potentially modify disease progression. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This narrative review focused on research investigating the impact of loneliness on the prevalence of dementia and its relationship with other risk factors. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) pathology affects the transentorhinal/entorhinal region early but whether entorhinal cortex (EC) astrocytes are causal drivers or therapeutic targets remains unresolved. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Triggered by LPS and AGEs in food, inflammatory cytokines can enter the brain and stimulate microglial activation, inflammation, and oxidative damage. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
However, knowledge alone does not consistently predict screening behavior. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease involves interacting mechanisms that include amyloid-beta accumulation, abnormal tau phosphorylation and aggregation, cholinergic dysfunction, synaptic degeneration, neuronal loss, neuroinflammation, vascular pathology, and genetic susceptibility. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Physical Examination.—Physical examination revealed that the patient was well developed, but poorly nourished, with an appearance of chronic illness. 1 key finding →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Down syndrome is one of the most common chromosomal abnormalities in humans in which an extra copy of chromosome 21 is present. 1 key finding →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS), caused by trisomy 21, is the most frequent genetic cause of intellectual disability worldwide. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid immunotherapy with lecanemab and donanemab has been approved on the basis of statistically significant slowing of cognitive and functional decline in early Alzheimer's disease (1,2). 2 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source
On June 7, 2021, the FDA granted accelerated approval to aducanumab (Aduhelm), the first new Alzheimer's drug approved since 2003 and the first ever approved for a mechanism thought to modify disease course. 3 key findings →
Design: regulatory decision Evidence: preliminary
Full summary, score breakdown and related studies → Original source
An independent US drug-pricing watchdog analyzed how lecanemab's actual price compares to its clinical benefit. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Respondents who reported no difficulty deciding (DECIDE = 2) had substantially lower odds of SCD than those who reported difficulty (DECIDE = 1; aOR approximately 0.13; FDR < 0.05). 1 key finding →
Design: post-hoc analysis Participants: 298,944 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADNI identified task-dependent performance boundaries, particularly attenuated conditional T discrimination within A+. 2 key findings →
Design: post-hoc analysis Participants: 1,097 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Public interest in cannabinoid medicines has outpaced the clinical pharmacology needed to judge product, dose and route. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Dynamic functional network connectivity (dFNC) commonly identifies recurring connectivity states from resting-state fMRI, but states derived independently in each dataset lack guaranteed correspondence across studies and cannot be directly estimated in new participants. 5 key findings →
Design: post-hoc analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source
Mitochondrial dysfunction, oxidative stress, neuroinflammation, and impaired protein homeostasis form interconnected pathological networks in acute central nervous system injury and chronic neurodegenerative disease. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
The impact of age and hearing loss on the brain has garnered significant attention, as both factors have been implicated in the development of cognitive impairment or dementia. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases are a growing global health burden associated with aging and characterized by progressive neuronal dysfunction, metabolic failure, mitochondrial impairment, oxidative stress, and chronic neuroinflammation. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases comprise a diverse group of progressive disorders characterized by the selective and irreversible loss of neuronal structure and function within the specific regions of the central and/or peripheral nervous systems. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Evidence for interventions that reduce refusal is strongest for music during personal care and modified bathing methods, with some support for positive communication and person-centred approaches, though quality is generally low and few studies involve family caregivers in community settings. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Apathy and depression are among the most common neuropsychiatric symptoms in dementia. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
The FDA gave lecanemab (Leqembi) accelerated approval based on Phase 2 data showing it reduced amyloid plaque in the brain, ahead of full Phase 3 results. 3 key findings →
Design: regulatory decision Evidence: early
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →